Vivascience's membrane adsorber chromatography technology will be combined with PerkinElmer's elution chemistries to create fractionation kits for proteomics-based biomarker analysis
PerkinElmer and Vivascience have entered into an agreement in biomarker screening and discovery.
This reagent platform will be incorporated into PerkinElmer's integrated biomarker screening solution that includes automated sample preparation with the Multiprobe II liquid handling workstation and world-class biomarker detection with the Protof 2000 Maldi O-Tof mass spectrometer.
"By working with a market leader like Vivascience, we are able to accelerate bringing breakthrough innovations to the emerging markets of proteomics-based biomarker screening and discovery," said Peter Coggins, president of PerkinElmer Life and Analytical Sciences.
"We are excited to pair our unparalleled MA technology with PerkinElmer's extensive range of proteomics expertise," said Matthias Keff, CEO of Vivascience.
"We are confident that the combined strength of PerkinElmer's state-of-the-art proteomic hardware and Vivascience's portfolio of membrane technology solutions will add significant value to the proteomics market".
PerkinElmer's biomarker screening solution is meeting with increasing excitement and acceptance in both the academic biomarker research community, as well as the emerging segment of biomarker-based research and diagnostic companies.
For example, Kevin Rosenblatt, a leading researcher in biomarker research and clinical proteomics at the University of Texas Southwestern, recently commented: "The combination of ultra-high mass accuracy and superb resolution over a broad mass range in the Protof, coupled with an automated biomarker enrichment platform, make the PerkinElmer approach an ideal biomarker discovery and screening platform".
In addition, Guy della Cioppa, senior vice president of business development at Predictive Diagnostics (PDI) said: "PDI is currently expanding its new facility and has adopted the PerkinElmer biomarker platform strategy as part of the development and implementation of new instrumentation and tools for its clinical proteomics programme".
Recently, PDI, a leading clinical proteomics company in the field of predictive diagnostics, adopted the Protof as part of its Bamf in silico biomarker platform.
It will have early access to the PerkinElmer/Vivascience fractionation kits through the end of the year.
Vivascience's MA technology, in contrast to traditional resins and beads, features a rigid format that makes it highly reproducible and robust.
The technology also has significant ease-of-use advantages when incorporated into the PerkinElmer biomarker screening solution, says the company.
The Protof 2000 is the cornerstone of the high content proteomics solution, a comprehensive approach to proteomics research pioneered by PerkinElmer.
Using advanced, innovative technologies, like the Protof 2000 Maldi MS, PerkinElmer has developed a suite of tools that it says achieve maximum meaningful data from any sample, improving results and reproducibility.
